These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 25317746)

  • 1. Characterization of S628N: a novel KIT mutation found in a metastatic melanoma.
    Vita M; Tisserand JC; Chauvot de Beauchêne I; Panel N; Tchertanov L; Agopian J; Mescam-Mancini L; Fouet B; Fournier B; Dubreuil P; Bertucci F; De Sepulveda P
    JAMA Dermatol; 2014 Dec; 150(12):1345-9. PubMed ID: 25317746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
    Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
    Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L576P KIT mutation in anal melanomas correlates with KIT protein expression and is sensitive to specific kinase inhibition.
    Antonescu CR; Busam KJ; Francone TD; Wong GC; Guo T; Agaram NP; Besmer P; Jungbluth A; Gimbel M; Chen CT; Veach D; Clarkson BD; Paty PB; Weiser MR
    Int J Cancer; 2007 Jul; 121(2):257-64. PubMed ID: 17372901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel somatic KIT exon 8 mutation with dramatic response to imatinib in a patient with mucosal melanoma: a case report.
    Rapisuwon S; Parks K; Al-Refaie W; Atkins MB
    Melanoma Res; 2014 Oct; 24(5):509-11. PubMed ID: 25003536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib (BMS-354825), a dual SRC/ABL kinase inhibitor, inhibits the kinase activity of wild-type, juxtamembrane, and activation loop mutant KIT isoforms associated with human malignancies.
    Schittenhelm MM; Shiraga S; Schroeder A; Corbin AS; Griffith D; Lee FY; Bokemeyer C; Deininger MW; Druker BJ; Heinrich MC
    Cancer Res; 2006 Jan; 66(1):473-81. PubMed ID: 16397263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin.
    Hodi FS; Corless CL; Giobbie-Hurder A; Fletcher JA; Zhu M; Marino-Enriquez A; Friedlander P; Gonzalez R; Weber JS; Gajewski TF; O'Day SJ; Kim KB; Lawrence D; Flaherty KT; Luke JJ; Collichio FA; Ernstoff MS; Heinrich MC; Beadling C; Zukotynski KA; Yap JT; Van den Abbeele AD; Demetri GD; Fisher DE
    J Clin Oncol; 2013 Sep; 31(26):3182-90. PubMed ID: 23775962
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anal mucosal melanoma with KIT-activating mutation and response to imatinib therapy--case report and review of the literature.
    Satzger I; Küttler U; Völker B; Schenck F; Kapp A; Gutzmer R
    Dermatology; 2010; 220(1):77-81. PubMed ID: 19996579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. KIT as a therapeutic target in metastatic melanoma.
    Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
    JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secondary c-Kit mutations confer acquired resistance to RTK inhibitors in c-Kit mutant melanoma cells.
    Todd JR; Becker TM; Kefford RF; Rizos H
    Pigment Cell Melanoma Res; 2013 Jul; 26(4):518-26. PubMed ID: 23582185
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412.
    de Melo Campos P; Machado-Neto JA; Scopim-Ribeiro R; Visconte V; Tabarroki A; Duarte AS; Barra FF; Vassalo J; Rogers HJ; Lorand-Metze I; Tiu RV; Costa FF; Olalla Saad ST; Traina F
    Leuk Res; 2014 Oct; 38(10):1245-51. PubMed ID: 25139846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. c-Kit inhibitors for unresectable or metastatic mucosal, acral or chronically sun-damaged melanoma: a systematic review and one-arm meta-analysis.
    Steeb T; Wessely A; Petzold A; Kohl C; Erdmann M; Berking C; Heppt MV
    Eur J Cancer; 2021 Nov; 157():348-357. PubMed ID: 34562816
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imatinib targeting of KIT-mutant oncoprotein in melanoma.
    Jiang X; Zhou J; Yuen NK; Corless CL; Heinrich MC; Fletcher JA; Demetri GD; Widlund HR; Fisher DE; Hodi FS
    Clin Cancer Res; 2008 Dec; 14(23):7726-32. PubMed ID: 19047099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecularly targeted therapies for melanoma.
    Liu LS; Colegio OR
    Int J Dermatol; 2013 May; 52(5):523-30. PubMed ID: 23590367
    [TBL] [Abstract][Full Text] [Related]  

  • 14. c-KIT signaling as the driving oncogenic event in sub-groups of melanomas.
    Smalley KS; Sondak VK; Weber JS
    Histol Histopathol; 2009 May; 24(5):643-50. PubMed ID: 19283671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene.
    Terheyden P; Houben R; Pajouh P; Thorns C; Zillikens D; Becker JC
    J Invest Dermatol; 2010 Jan; 130(1):314-6. PubMed ID: 19812602
    [No Abstract]   [Full Text] [Related]  

  • 16. A phase 2 trial of dasatinib in patients with locally advanced or stage IV mucosal, acral, or vulvovaginal melanoma: A trial of the ECOG-ACRIN Cancer Research Group (E2607).
    Kalinsky K; Lee S; Rubin KM; Lawrence DP; Iafrarte AJ; Borger DR; Margolin KA; Leitao MM; Tarhini AA; Koon HB; Pecora AL; Jaslowski AJ; Cohen GI; Kuzel TM; Lao CD; Kirkwood JM
    Cancer; 2017 Jul; 123(14):2688-2697. PubMed ID: 28334439
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic activation of KIT in distinct subtypes of melanoma.
    Curtin JA; Busam K; Pinkel D; Bastian BC
    J Clin Oncol; 2006 Sep; 24(26):4340-6. PubMed ID: 16908931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A new KIT mutation (N505I) in acral melanoma confers constitutive signaling, favors tumorigenic properties, and is sensitive to imatinib.
    Allegra M; Giacchero D; Segalen C; Dumaz N; Butori C; Hofman V; Hofman P; Lacour JP; Bertolotto C; Bahadoran P; Ballotti R
    J Invest Dermatol; 2014 May; 134(5):1473-1476. PubMed ID: 24317392
    [No Abstract]   [Full Text] [Related]  

  • 19. Clinical responses observed with imatinib or sorafenib in melanoma patients expressing mutations in KIT.
    Handolias D; Hamilton AL; Salemi R; Tan A; Moodie K; Kerr L; Dobrovic A; McArthur GA
    Br J Cancer; 2010 Apr; 102(8):1219-23. PubMed ID: 20372153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumour heterogeneity of mucosal melanomas during treatment with imatinib.
    Schoenewolf NL; Urosevic-Maiwald M; Dummer R
    Br J Dermatol; 2011 Aug; 165(2):419-24. PubMed ID: 21495997
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.